Breyanzi showed significant efficacy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma, achieving primary and secondary endpoints in the TRANSCEND FL trial. Marginal zone lymphoma, a slow ...

The FDA accepted Breyanzi's sBLA for relapsed/refractory marginal zone lymphoma, granting priority review with a PDUFA date of December 5, 2025. Breyanzi is a CAR-T cell therapy targeting CD19, with a ...

Please provide your email address to receive an email when new articles are posted on . Axicabtagene ciloleucel induced durable responses for patients with relapsed or refractory indolent non-Hodgkin ...

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients ...

Orphan Drug Designation confers regulatory, financial and strategic advantagesEO2463 has shown potentially disease modifying activity in clinical ...

The FDA has approved lisocabtagene maraleucel (Breyanzi, Bristol-Myers Squibb) for relapsed or refractory marginal zone lymphoma (MZL) in adults after at least two prior lines of systemic therapy.

What Is Breyanzi, and Why Does It Matter? Breyanzi (lisocabtagene maraleucel) is a type of personalized cancer treatment called chimeric antigen receptor (CAR) T-cell therapy, which uses your modified ...

Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi). "Patients living with marginal zone lymphoma .

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

– ZUMA-5 Analysis Shows Median Progression-Free Survival of 62.2 Months and Median Duration of Response of 60.4 Months After Median Follow-Up of More Than Five Years – – Over Half of Patients Alive at ...